Relmada Therapeutics (NASDAQ:RLMD) Issues Earnings Results

Relmada Therapeutics (NASDAQ:RLMD) released its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.09, FiscalAI reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

• NDV-01 remains on track for registrational development: Relmada plans to file the IND by year-end 2026 and begin the Phase III rescue program after clearance, with approximately 80 clinical sites prepared and 60 designated as primary sites.
• Phase II results support NDV-01’s potential: The company reported a 95% complete response rate at any time and a 76% durable complete response rate at 12 months, with favorable safety and tolerability.
• Manufacturing is the key near-term execution risk. Formulation, process development, and analytical work are complete, but Relmada still needs to secure GMP manufacturing capacity, produce batches, and generate sufficient stability data before filing the IND.
• Relmada reported substantial financial runway: Cash, cash equivalents, and short-term investments totaled $217.7 million at quarter-end, which management expects to fund operations through 2029, including completion of the NDV-01 Phase III rescue program.
• The company has not yet finalized the timing or format of additional clinical disclosures; management suggested that six-month data and a larger patient sample may be more meaningful than the previously anticipated three-month results, potentially shifting disclosure into the first half of 2027.

Relmada Therapeutics Stock Performance

Shares of RLMD stock traded down $0.43 during trading hours on Friday, reaching $4.94. The company had a trading volume of 2,125,013 shares, compared to its average volume of 1,542,462. The business has a fifty day moving average price of $6.05 and a 200-day moving average price of $5.93. Relmada Therapeutics has a one year low of $0.55 and a one year high of $8.00. The firm has a market cap of $518.16 million, a PE ratio of -5.49 and a beta of 0.46.

Institutional Investors Weigh In On Relmada Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new position in shares of Relmada Therapeutics in the 4th quarter worth $35,041,000. Squadron Capital Management LLC purchased a new stake in Relmada Therapeutics during the fourth quarter valued at $32,361,000. Adage Capital Partners GP L.L.C. bought a new position in Relmada Therapeutics in the fourth quarter valued at about $20,624,000. Marshall Wace LLP boosted its position in Relmada Therapeutics by 1,072.4% in the fourth quarter. Marshall Wace LLP now owns 3,189,662 shares of the company’s stock worth $15,406,000 after purchasing an additional 2,917,609 shares during the last quarter. Finally, Orbimed Advisors LLC bought a new stake in shares of Relmada Therapeutics during the 4th quarter valued at about $12,609,000. Institutional investors own 45.24% of the company’s stock.

Analysts Set New Price Targets

RLMD has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relmada Therapeutics in a report on Thursday, June 18th. HC Wainwright initiated coverage on shares of Relmada Therapeutics in a research report on Thursday, June 18th. They set a “buy” rating and a $12.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.